CompoSecure Q2 Earnings Call Highlights

GPGI reported Q2 results that met expectations, with growth at CompoSecure offsetting continued market-driven weakness at Husky. The company reiterated its full-year 2026 revenue, adjusted EBITDA, and free-cash-flow outlook, while narrowing its adjusted EBITDA margin guidance due to tariff pass-through revenue and Husky product mix. Overall messaging is steady but tempered by ongoing weakness in Husky and margin headwinds from tariffs.

Analysis

CMPO looks like the cleaner signal in the mix: if its growth is still offsetting a weak legacy segment, that usually means the core program pipeline is healthy enough to hold share and pricing, even if the consolidated numbers are being muddied by cyclical noise elsewhere. The market should care more about whether CMPO’s growth is tied to new issuer launches and retention economics than to the headline revenue print, because the former supports a higher quality multiple while the latter can fade quickly.

The EBITDA-margin guide revision is the important tell. Tariff pass-through revenue can flatter top-line growth without adding much incremental profit, so investors who anchor on revenue may overestimate operating leverage. That creates a second-order loser in the broader card/industrial value chain: low-margin suppliers and pass-through-heavy businesses can look busier without actually improving FCF conversion, which tends to compress valuation once the market looks through the noise.

Catalyst-wise, the next 1-3 months matter more than the day-one reaction. The thesis is falsified if CMPO’s next update shows weaker organic growth ex-pass-through, a wider margin downgrade, or any deterioration in free-cash-flow conversion; conversely, another clean beat on EBITDA/FCF would support a re-rating. Over 6-18 months, the structural bull case is premium-card penetration and mix uplift, but only if issuer demand stays stable and tariff-related revenue does not become the dominant driver.

Key Decisions for Investors

• Stay neutral-to-slightly constructive on CMPO for now; add on post-print weakness only if the stock sells off >5% and management confirms organic growth is intact on the next call.
• Avoid chasing the revenue headline: require evidence that EBITDA and FCF are growing faster than tariff-pass-through revenue before paying up for the multiple.
• For a hedged expression, pair a small long CMPO with a short basket/ETF hedge in cyclical industrial exposure (e.g., XLI) for 1-3 months to isolate quality-growth vs. margin-noise risk.
• Set a watch item for the next quarterly margin bridge; if margins narrow again despite stable tariff assumptions, the thesis is broken and the name should be de-rated.